12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Simbrinza brinzolamide/brimonidine tartrate regulatory update

Novartis' Alcon Inc. ophthalmic unit said FDA approved Simbrinza brinzolamide/brimonidine tartrate to reduce intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. The product is...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >